Macrogenics (MGNX)

MacroGenics, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel, which is in phase 2 clinical trials. It is also being investigated for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer, which has completed phase 1 clinical trials. Additionally, MacroGenics is developing MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an antibody-drug conjugate (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials. MGC030 is another ADC molecule for the treatment of solid tumors, which is currently in preclinical trials. The company is also developing next-generation T-cell engager programs. MacroGenics has collaborations with TerSera Therapeutics LLC, Incyte Corporation, and Gilead Sciences, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.